Pacgen Life Science Corp  

(Public, CVE:PBS)   Watch this stock  
Find more results for CVE:pga
+0.0050 (20.00%)
Mar 30 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.03 - 0.03
52 week 0.01 - 0.05
Open 0.03
Vol. 83,000.00
Mkt cap 1.42M
P/E 3.28
Div/yield     -
EPS 0.01
Shares 47.22M
Beta 0.89
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin 53.78% 142.91%
Operating margin 50.56% 138.10%
EBITD margin - 138.34%
Return on average assets 24.27% 137.00%
Return on average equity 125.02% -
Employees 10 -
CDP Score - -


Suite 1500, 701 West Georgia Street
+1-604-4364388 (Phone)
+1-604-4364380 (Fax)

Website links


Pacgen Life Science Corporation is a Canada-based life science technology company. The Company is focused on the commercialization of biomedical products and services, including its previous development of novel therapeutic drug candidates. The Company´┐Żs products include: Fit X1, Electronic Pipettes and A+ Pipette Controller. Fit X 401 is an automated, high-precision pipetting system specifically designed to replace the manual process of PCR/qPCR sample preparation. A+ Pipette Controller is an electronic pipette controller designed for use with graduated and volumetric glass and plastic pipets. The Company has reported positive results from its Phase IIb dose-ranging clinical trial for its lead product candidate, PAC-113, a novel anti-fungal drug.

Officers and directors

Chung-Yu Wang Chairman of the Board, Interim President and Chief Executive Officer
Christina Yip Chief Financial Officer, Corporate Secretary
Telvin Ju Ph.D. Lead Independent Director
Jeng-Horng Her Ph.D. Independent Director
Min-Chih Hsuan Independent Director
Age: 60
Frederick Huang Independent Director